Skip to the content
[email protected]
Get in Touch
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
Menu
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
NEWS
Archives 2018
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
Archives 2021
Archives 2020
Archives 2019
Archives 2018
Archives 2017
Archives 2016
Archives 2021
Archives 2020
Archives 2019
Archives 2018
Archives 2017
Archives 2016
October 1, 2018
Appili Therapeutics Appoints Veteran Drug Development Executive, Dr. Armand Balboni, as Its Inaugural Chief Scientific Officer
Read More
August 16, 2018
Appili Therapeutics Announces Results of 2018 Annual and Special Meeting
Read More
July 30, 2018
Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension
Read More
June 21, 2018
Appili Therapeutics to Present at 2018 Atlantic Venture Forum Technology Showcase
Read More
April 18, 2018
Appili Therapeutics to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference
Read More
February 7, 2018
Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline
Read More
January 26, 2018
Appili Recognized as ‘New Business of the Year’ by the Halifax Chamber of Commerce
Read More
January 9, 2018
Appili Therapeutics Licenses BioTerrorism Vaccine Rights
Read More
